



Proteomic Insights into Cancer Initiation and Evolution

Guest Editor:

Dr. Xinyan Wu

1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA
2. Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA

Deadline for manuscript submissions:

31 August 2024

Message from the Guest Editor

Proteomics has emerged as a powerful tool for dissecting the intricate networks of proteins and their interactions, providing insights into how aberrations in protein expression, post-translational modifications, and signaling pathways drive tumorigenesis. This Special Issue will delve into proteomic approaches that unveil the molecular signatures of cancer, identify novel biomarkers, and offer an enhanced understanding of the tumor microenvironment.

From the discovery of subtype-specific biomarkers to uncovering potential therapeutic targets, this Special Issue aims to offer a comprehensive overview of how proteomics is shaping cancer research. We invite authors to submit original research and review articles that focus on the innovative applications of proteomics in unraveling the complexities of cancer biology and translating these findings into clinical advances.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI